Strides Pharma Science (NSE:STAR) 6-Month Price Index: 1.32 (As of Sep. 15, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NSE:STAR Strides Pharma Science Ltd NSE:STAR
68 GF Score
Price ₹1,183.40
GF Value ₹863.22
Valuation Significantly Overvalued
! 3 Warning Signs
View Full Analysis

What is Strides Pharma Science 6-Month Price Index?

Strides Pharma Science NSE:STAR -2.76% 68 6-Month Price Index is 1.32 as of Sep. 15, 2026. GuruFocus rates NSE:STAR with a GF Score™ of 68/100 and a GF Value™ of ₹863.22 (Significantly Overvalued). The stock has 3 warning signs investors should review.

6-Month Price Index is an intermediate-term momentum that shows the price change relative to 6-month ago. It’s calculated by current share price divided by share price 6-months ago. As of today (2026-09-15), Strides Pharma Science's 6-Month Price Index is 1.32.

Strides Pharma Science  (NSE:STAR) 6-Month Price Index Explanation

Price Index (PI) also called momentum. Strategies involving Price Index are also known as momentum strategies as they allow investors to profit from a company’s stock price. 6-Month Price Index is an intermediate-term momentum that shows the price change relative to 6-month ago.

The investment strategy for momentum investors is to buy winners and sell losers. That is, buy stocks that performed well and sell stocks that performed poorly in the past.

Strides Pharma Science 6-Month Price Index Related Terms

NSE:STAR vs ZTS: 6-Month Price Index Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Strides Pharma Science's 6-Month Price Index, along with its competitors' market caps and 6-Month Price Index data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

NSE:STAR
68GF Score
Strides Pharma Science Ltd NSE:STAR
6-Month Price Index is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Strides Pharma Science  (NSE:STAR) 6-Month Price Index Calculation

6-Month Price Index is calculated as following:

6-Month Price Index=Current Share Price / Share Price 6-Months Ago

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about 6-Month Price Index →
What does a 6-Month Price Index of 1.32 mean?
Strides Pharma Science (NSE:STAR) has a 6-Month Price Index of 1.32 as of Sep. 15, 2026. 6-Month Price Index is an intermediate-term momentum that shows the price change relative to 6-month ago. View historical data on Strides Pharma Science and its competitors.
Is Strides Pharma Science's 6-Month Price Index too high?
Strides Pharma Science's current 6-Month Price Index is 1.32. Overall, Strides Pharma Science has a GF Score™ of 68/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Strides Pharma Science's 6-Month Price Index compare to ZTS?
Strides Pharma Science's 6-Month Price Index of 1.32 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 6-Month Price Index for a Drug Manufacturers company?
A good 6-Month Price Index depends on the Drug Manufacturers industry context. However, 6-Month Price Index should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 6-Month Price Index mean?
A high 6-Month Price Index can signal that a stock is expensive relative to its fundamentals. 6-Month Price Index is an intermediate-term momentum that shows the price change relative to 6-month ago. View historical data on Strides Pharma Science and its competitors. Strides Pharma Science's current 6-Month Price Index is 1.32. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Strides Pharma Science stock overvalued right now?
Based on GuruFocus' analysis, Strides Pharma Science (NSE:STAR) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹863.22, compared to a current price of ₹1,183.40 — trading 37.1% above its estimated fair value. The current 6-Month Price Index is 1.32. Strides Pharma Science's overall GF Score™ is 68/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 6-Month Price Index calculated?
6-Month Price Index is calculated from a company's financial statements. For Strides Pharma Science (NSE:STAR), the current 6-Month Price Index is 1.32 as of Sep. 15, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Strides Pharma Science (NSE:STAR) Overvalued in 2026?

Based on GuruFocus' analysis, Strides Pharma Science stock appears to be overvalued. The current stock price of ₹1,183.40 is trading 37.1% above its estimated GF Value™ of ₹863.22. GuruFocus considers Strides Pharma Science to be Significantly Overvalued.

Key valuation signals for NSE:STAR:

  • 6-Month Price Index: 1.32
  • GF Value™: ₹863.22 vs. price of ₹1,183.40 (37.1% above fair value)
  • GF Score™: 68/100 with 3 warning signs

No single metric tells the full story. See the NSE:STAR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Strides Pharma Science Business Description

Other Exchanges 532531:India
Address Bannerghatta Road, Strides House, Bilekahalli, Bengaluru, KA, IND, 560076
Strides Pharma Science Ltd develops and manufactures a wide range of IP-led niche pharmaceutical products. Its diverse portfolio spans complex generics across multiple dosage forms, including tablets, hard capsules, sachets, liquids, nasal sprays, topicals, and controlled substances. It also manufactures drugs in the anti-retroviral, anti-malarial, anti-tuberculosis, Hepatitis, and other infectious disease drug segments for its institutional business. The customers for this business include institutionally funded aid projects and procurement agencies. With its R&D, integration, and distribution network, the company brings differentiated products to market across the U.S., Australia, Europe, Africa, and Emerging Markets. Geographically, it generates maximum revenue from North America.
68GF Score

Get the complete analysis for NSE:STAR

6-Month Price Index is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹1,183.40
Price
₹863.22
GF Value